Skip to main content
. 2018 Jun 12;119(2):241–247. doi: 10.1038/s41416-018-0129-3

Table 4.

Tumour response to sorafenib

All <75 years (N = 397) ≥75 years (N = 397) P value
CR, n (%) 20 (2.7) 7 (1.9) 13 (3.6) 0.3883
PR, n (%) 186 (25.4) 90 (24.2) 96 (26.7)
SD, n (%) 427 (58.3) 224 (60.2) 203 (56.4)
PD, n (%) 95 (13.0) 50 (13.4) 45 (12.5)
NE, n (%) 4 (0.6) 1 (0.3) 3 (0.8)
ORR, % 28.1 26.1 30.3
DCR, % 86.5 86.3 86.7

CR complete response, DCR disease control rate, NE not evaluable, ORR objective response rate, PD progressive disease, PR partial response, SD stable disease